Oncology Venture extends the subscription period of the current rights issue

NEXT STORY
Oncology Venture can inform that the last trading day of the Subscription Rights is now 19 November 2019, following the extension of subscription period until the 21 November of the current rights issue
PREV STORY
Oncology Venture advancing towards next milestone in its clinical development of 2X-121.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Oncology Venture extends the subscription period of the current rights issue

NEXT STORY
Oncology Venture can inform that the last trading day of the Subscription Rights is now 19 November 2019, following the extension of subscription period until the 21 November of the current rights issue
PREV STORY
Oncology Venture advancing towards next milestone in its clinical development of 2X-121.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The Europe diabetes care devices market is expected to reach US$ 11,184.6 Mn in 2027 from US$ 6,853.3 Mn in 2018

author_avatar
NASDAQ Market News

Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer

author_avatar
NASDAQ Market News

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021

author_avatar
NASDAQ Market News